Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06753890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

Name: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) — clinical trial record (NCT06753890)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorTasly Pharmaceutical Group Co., Ltd

Started2024-12-30

View on ClinicalTrials.gov ↗

Tasly Pharmaceutical Group Co., Ltd

19 trials monitored

See 1 trial at risk

This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)

Trial Details

NCT Number	NCT06753890
Lead Sponsor	Tasly Pharmaceutical Group Co., Ltd
Conditions	Diarrhea-predominant Irritable Boewl Syndrome
Enrollment	520 participants
Start Date	2024-12-30
Primary Completion	2026-11-11 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-31